Research Article

Soluble IL-2 Receptor: A Biomarker for Assessing Myositis Activity

Table 1

Clinical data on patients with IM.

PatientAge/sex DiagnosisProximal muscle weaknessDM skin rash Muscle enzymesAnti-Jo1 antibodiesAbnormal EMG findingsAbnormal muscle biopsy findingsMedication

120/FPM/MCTD+++Pred., MTX
246/FPM++++Pred., MTX
331/FPM++++Pred., MTX
465/FPM+++Pred., MTX
547/FPM/ILD+++NR+Pred., MTX, IVIG
672/HPM+++Pred.
767/FPM++++Pred.
827/FPM/MCTD+++Pred., AZA
941/HPM+++++Pred., MTX
1072/HPM/HCV++++Pred., IVIG
1161/FPM++++Pred.
1238/FPM/ILD+++++Pred., MTX
1361/HPM+++Pred., MTX, IVIG
1457/FPM/MCTD++++Pred., MTX, chloroquine
1577/FPM++++Pred.
1663/HPM/ILD+++++Pred.
1748/FPM+++Pred., MTX, IVIG, AZA
1837/HDM+++++Pred., MTX
1942/FDM++++Pred., MTX, IVIG
2056/HDM++++Pred., MTX, chloroquine
2144/HDM++++Pred., MTX, IVIG
2214/FDM+++++Pred.
2367/HDM+++++Pred.
2440/FDM+++++Pred., MTX
2540/FDM++++++Pred., MTX, IVIG, AZA, CSA
2674/HIBM++++Pred.
2769/FIBM++++Pred., MTX, IVIG

MCTD: mixed connective tissue disease; ILD: interstitial lung disease; HCV: hepatitis C virus; Pred.: prednisone; MTX: methotrexate; IVIG: intravenous immunoglobulin; AZA: azathioprine; CSA: cyclosporine; NR: not reported or not done.